TCRX Q3 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+139.4% YoY

Gross Profit

$2M69.5% margin

Operating Income

-$37M-1475.6% margin

Net Income

-$36M-1422.1% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-18.4%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$34M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$262M

Total Liabilities

$118M

Stockholders' Equity

$144M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+139.4%
Gross Profit	$2M	$1M	+66.3%
Operating Income	-$37M	-$33M	-13.6%
Net Income	-$36M	-$30M	-19.5%

Revenue Segments

Reportable Segment

$3M100%